{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:34:19Z","timestamp":1787009659542,"version":"build-2736575974"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T00:00:00Z","timestamp":1749427200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Withdrawal of DMARD therapy to determine need for ongoing medication is common in JIA management. Little is known about how often patients undergo trials of medication discontinuation or the outcomes of successive trials. This study examined DMARD treatment cycles in a JIA cohort to determine how frequently medication withdrawal trials occur over follow-up and if relapse rates change over consecutive cycles.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a retrospective review of longitudinal cohort data of children with DMARD-treated JIA diagnosed between 2010 and 2014. Extracted data included demographics, DMARD therapy details and clinical assessments including active joint count, date of last follow-up and disease status at that time. Data were collected to January 2024.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Ninety-one children were studied. Median age was 10.1\u2009years (range 1.5\u201316.8), 59% were female and median follow-up was 7.0\u2009years (range 0.7\u201313). A maximum of four cycles of DMARD treatment were undertaken. Forty-four percent of children underwent more than one cycle; 63.5% relapsed after their first cycle and 53.3% after their second; and 25.3% remained off treatment to last follow-up following cycle 1, and over two subsequent cycles of therapy this increased to just 35.2%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In JIA patients requiring DMARD therapy, recurrent treatment withdrawal trials are common over follow-up, but relapse risk is high and remains so over successive trials. Permanent treatment withdrawal is therefore not a realistic goal for most patients with therapies currently available. Until biomarkers of permanent remission are developed, strategies to minimize both drug toxicity and the risk of disease flares in patients with recurrently active disease after medication withdrawal are required.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaf321","type":"journal-article","created":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T07:49:44Z","timestamp":1749196184000},"page":"5439-5445","source":"Crossref","is-referenced-by-count":2,"title":["Disease modifying anti-rheumatic drug treatment cycles and rates of flare in juvenile idiopathic arthritis\u2014a tale of Sisyphean endeavour?"],"prefix":"10.1093","volume":"64","author":[{"given":"Emily","family":"Bugeja","sequence":"first","affiliation":[{"name":"Rheumatology Service, Department of General Medicine, The Royal Children\u2019s Hospital , Melbourne,","place":["Australia"]},{"name":"The Royal Melbourne Hospital , Melbourne,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgina","family":"Tiller","sequence":"additional","affiliation":[{"name":"Rheumatology Service, Department of General Medicine, The Royal Children\u2019s Hospital , Melbourne,","place":["Australia"]},{"name":"Monash Children\u2019s Hospital , Melbourne,","place":["Australia"]},{"name":"Murdoch Children\u2019s Research Institute , Melbourne,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Renton","sequence":"additional","affiliation":[{"name":"Rheumatology Service, Department of General Medicine, The Royal Children\u2019s Hospital , Melbourne,","place":["Australia"]},{"name":"Monash Children\u2019s Hospital , Melbourne,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Munro","sequence":"additional","affiliation":[{"name":"Rheumatology Service, Department of General Medicine, The Royal Children\u2019s Hospital , Melbourne,","place":["Australia"]},{"name":"Murdoch Children\u2019s Research Institute , Melbourne,","place":["Australia"]},{"name":"The University of Melbourne , Melbourne,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Gowdie","sequence":"additional","affiliation":[{"name":"Rheumatology Service, Department of General Medicine, The Royal Children\u2019s Hospital , Melbourne,","place":["Australia"]},{"name":"Monash Children\u2019s Hospital , Melbourne,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Cox","sequence":"additional","affiliation":[{"name":"Rheumatology Service, Department of General Medicine, The Royal Children\u2019s Hospital , Melbourne,","place":["Australia"]},{"name":"Monash Children\u2019s Hospital , Melbourne,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Allen","sequence":"additional","affiliation":[{"name":"Rheumatology Service, Department of General Medicine, The Royal Children\u2019s Hospital , Melbourne,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo","family":"Buckle","sequence":"additional","affiliation":[{"name":"Rheumatology Service, Department of General Medicine, The Royal Children\u2019s Hospital , Melbourne,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Akikusa","sequence":"additional","affiliation":[{"name":"Rheumatology Service, Department of General Medicine, The Royal Children\u2019s Hospital , Melbourne,","place":["Australia"]},{"name":"Murdoch Children\u2019s Research Institute , Melbourne,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,6,9]]},"reference":[{"key":"2025100315120539100_keaf321-B1","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s12969-021-00607-0","article-title":"Clinical remission and subsequent relapse in patients with juvenile idiopathic arthritis: predictive factors according to therapeutic approach","volume":"19","author":"Castillo-Vilella","year":"2021","journal-title":"Pediatr Rheumatol Online J"},{"key":"2025100315120539100_keaf321-B2","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1136\/annrheumdis-2018-213030","article-title":"Treating juvenile idiopathic arthritis to target: recommendations of an international task force","volume":"77","author":"Ravelli","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2025100315120539100_keaf321-B3","first-page":"2290","article-title":"Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis","volume":"31","author":"Wallace","year":"2004","journal-title":"J Rheumatol"},{"key":"2025100315120539100_keaf321-B4","doi-asserted-by":"crossref","first-page":"e15189","DOI":"10.1111\/1756-185X.15189","article-title":"Three- and five-year outcomes of an inception cohort of Australian children with juvenile idiopathic arthritis","volume":"27","author":"Tiller","year":"2024","journal-title":"Int J Rheum Dis"},{"key":"2025100315120539100_keaf321-B5","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s40272-019-00362-6","article-title":"Treatment withdrawal following remission in juvenile idiopathic arthritis: a systematic review of the literature","volume":"21","author":"Halyabar","year":"2019","journal-title":"Paediatr Drugs"},{"key":"2025100315120539100_keaf321-B6","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1002\/art.30426","article-title":"Ongoing disease activity and changing categories in a long-term nordic cohort study of juvenile idiopathic arthritis","volume":"63","author":"Nordal","year":"2011","journal-title":"Arthritis Rheum"},{"key":"2025100315120539100_keaf321-B7","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/acr.20044","article-title":"Early outcomes and improvement of patients with juvenile idiopathic arthritis enrolled in a Canadian multicenter inception cohort","volume":"62","author":"Oen","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025100315120539100_keaf321-B8","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12969-018-0288-z","article-title":"Juvenile idiopathic arthritis managed in the new millennium: one year outcomes of an inception cohort of Australian children","volume":"16","author":"Tiller","year":"2018","journal-title":"Pediatr Rheumatol Online J"},{"key":"2025100315120539100_keaf321-B9","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/acr.22477","article-title":"Impact of medication withdrawal method on flare-free survival in patients with juvenile idiopathic arthritis on combination therapy","volume":"67","author":"Chang","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025100315120539100_keaf321-B10","first-page":"1574","article-title":"Frequency of relapse after discontinuation of methotrexate therapy for clinical remission in juvenile rheumatoid arthritis","volume":"22","author":"Ravelli","year":"1995","journal-title":"J Rheumatol"},{"key":"2025100315120539100_keaf321-B11","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/acr.24994","article-title":"Disease recapture rates after medication discontinuation and flare in juvenile idiopathic arthritis: an observational study within the Childhood Arthritis and Rheumatology Research Alliance Registry","volume":"75","author":"Ringold","year":"2023","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025100315120539100_keaf321-B12","doi-asserted-by":"crossref","first-page":"426","DOI":"10.55563\/clinexprheumatol\/rxidz4","article-title":"Analysis of arthritis flares after achievement of inactive disease with methotrexate monotherapy in juvenile idiopathic arthritis","volume":"39","author":"Bava","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"2025100315120539100_keaf321-B13","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1001\/jama.2010.375","article-title":"Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial","volume":"303","author":"Foell","year":"2010","journal-title":"JAMA"},{"key":"2025100315120539100_keaf321-B14","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s12969-022-00769-5","article-title":"Discontinuation of biologic DMARDs in non-systemic JIA patients: a scoping review of relapse rates and associated factors","volume":"20","author":"Gieling","year":"2022","journal-title":"Pediatr Rheumatol Online J"},{"key":"2025100315120539100_keaf321-B15","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1542\/peds.100.6.994","article-title":"Discontinuation of methotrexate treatment in juvenile rheumatoid arthritis","volume":"100","author":"Gottlieb","year":"1997","journal-title":"Pediatrics"},{"key":"2025100315120539100_keaf321-B16","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1002\/acr.23435","article-title":"Flares after withdrawal of biologic therapies in juvenile idiopathic arthritis: clinical and laboratory correlates of remission duration","volume":"70","author":"Simonini","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025100315120539100_keaf321-B17","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1136\/annrheumdis-2014-207164","article-title":"The risk and nature of flares in juvenile idiopathic arthritis: results from the ReACCh-Out cohort","volume":"75","author":"Guzman","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2025100315120539100_keaf321-B18","doi-asserted-by":"crossref","first-page":"602","DOI":"10.46497\/ArchRheumatol.2023.10035","article-title":"Risk of flare in juvenile idiopathic arthritis: is it related to the methotrexate treatment strategy or patient characteristics?","volume":"38","author":"\u0130\u015fg\u00fcder","year":"2023","journal-title":"Arch Rheumatol"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keaf321\/63458100\/keaf321.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/10\/5439\/63458100\/keaf321.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/10\/5439\/63458100\/keaf321.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T19:12:18Z","timestamp":1759518738000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/10\/5439\/8159073"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,9]]},"references-count":18,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,6,9]]},"published-print":{"date-parts":[[2025,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaf321","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,6,9]]}}}